Template:HSV-1 antiviral treatment: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
*Antiviral drug options: | *Antiviral drug options: | ||
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days | **[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days | ||
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan" /> | ***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref> | ||
**[[Valacyclovir]] (significantly higher bioavailability than acyclovir) | **[[Valacyclovir]] (significantly higher bioavailability than acyclovir) | ||
**[[Famciclovir]] | **[[Famciclovir]] | ||
Revision as of 21:29, 25 April 2016
Anti-viral Treatment
Treatment does not affect dormant virus in nerve ganglions → recurrent disease remains possible
- Antiviral drug options:
- Acyclovir 40-80mg/kg PO divided in 3-4 doses for 5-7 days
- Can also be used as a cream or oral suspension (swish and swallow)[1]
- Valacyclovir (significantly higher bioavailability than acyclovir)
- Famciclovir
- Acyclovir 40-80mg/kg PO divided in 3-4 doses for 5-7 days
- ↑ Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.